title: VAV3 mediates resistance to breast cancer endocrine therapy.
abstract: BACKGROUND
  Endocrine therapies targeting cell proliferation and survival mediated by estrogen receptor α (ERα) are among the most effective systemic treatments for ERα-positive breast cancer. However, most tumors initially responsive to these therapies acquire resistance through mechanisms that involve ERα transcriptional regulatory plasticity. Herein we identify VAV3 as a critical component in this process.
  
  
  METHODS
  A cell-based chemical compound screen was carried out to identify therapeutic strategies against resistance to endocrine therapy. Binding to ERα was evaluated by molecular docking analyses, an agonist fluoligand assay and short hairpin (sh)RNA-mediated protein depletion. Microarray analyses were performed to identify altered gene expression. Western blot analysis of signaling and proliferation markers, and shRNA-mediated protein depletion in viability and clonogenic assays, were performed to delineate the role of VAV3. Genetic variation in VAV3 was assessed for association with the response to tamoxifen. Immunohistochemical analyses of VAV3 were carried out to determine its association with therapeutic response and different tumor markers. An analysis of gene expression association with drug sensitivity was carried out to identify a potential therapeutic approach based on differential VAV3 expression.
  
  
  RESULTS
  The compound YC-1 was found to comparatively reduce the viability of cell models of acquired resistance. This effect was probably not due to activation of its canonical target (soluble guanylyl cyclase), but instead was likely a result of binding to ERα. VAV3 was selectively reduced upon exposure to YC-1 or ERα depletion, and, accordingly, VAV3 depletion comparatively reduced the viability of cell models of acquired resistance. In the clinical scenario, germline variation in VAV3 was associated with the response to tamoxifen in Japanese breast cancer patients (rs10494071 combined P value = 8.4 × 10-4). The allele association combined with gene expression analyses indicated that low VAV3 expression predicts better clinical outcome. Conversely, high nuclear VAV3 expression in tumor cells was associated with poorer endocrine therapy response. Based on VAV3 expression levels and the response to erlotinib in cancer cell lines, targeting EGFR signaling may be a promising therapeutic strategy.
  
  
  CONCLUSIONS
  This study proposes VAV3 as a biomarker and a rationale for its use as a signaling target to prevent and/or overcome resistance to endocrine therapy in breast cancer.
authors.forename: Helena
authors.initials: H
authors.lastname: Aguilar
authors.forename: Ander
authors.initials: A
authors.lastname: Urruticoechea
authors.forename: Pasi
authors.initials: P
authors.lastname: Halonen
authors.forename: Kazuma
authors.initials: K
authors.lastname: Kiyotani
authors.forename: Taisei
authors.initials: T
authors.lastname: Mushiroda
authors.forename: Xavier
authors.initials: X
authors.lastname: Barril
authors.forename: Jordi
authors.initials: J
authors.lastname: Serra-Musach
authors.forename: Abul
authors.initials: A
authors.lastname: Islam
authors.forename: Livia
authors.initials: L
authors.lastname: Caizzi
authors.forename: Luciano
authors.initials: L
authors.lastname: Di Croce
authors.forename: Ekaterina
authors.initials: E
authors.lastname: Nevedomskaya
authors.forename: Wilbert
authors.initials: W
authors.lastname: Zwart
authors.forename: Josefine
authors.initials: J
authors.lastname: Bostner
authors.forename: Elin
authors.initials: E
authors.lastname: Karlsson
authors.forename: Gizeh
authors.initials: G
authors.lastname: Pérez Tenorio
authors.forename: Tommy
authors.initials: T
authors.lastname: Fornander
authors.forename: Dennis C
authors.initials: DC
authors.lastname: Sgroi
authors.forename: Rafael
authors.initials: R
authors.lastname: Garcia-Mata
authors.forename: Maurice P H M
authors.initials: MP
authors.lastname: Jansen
authors.forename: Nadia
authors.initials: N
authors.lastname: García
authors.forename: Núria
authors.initials: N
authors.lastname: Bonifaci
authors.forename: Fina
authors.initials: F
authors.lastname: Climent
authors.forename: María Teresa
authors.initials: MT
authors.lastname: Soler
authors.forename: Alejo
authors.initials: A
authors.lastname: Rodríguez-Vida
authors.forename: Miguel
authors.initials: M
authors.lastname: Gil
authors.forename: Joan
authors.initials: J
authors.lastname: Brunet
authors.forename: Griselda
authors.initials: G
authors.lastname: Martrat
authors.forename: Laia
authors.initials: L
authors.lastname: Gómez-Baldó
authors.forename: Ana I
authors.initials: AI
authors.lastname: Extremera
authors.forename: Agnes
authors.initials: A
authors.lastname: Figueras
authors.forename: Josep
authors.initials: J
authors.lastname: Balart
authors.forename: Robert
authors.initials: R
authors.lastname: Clarke
authors.forename: Kerry L
authors.initials: KL
authors.lastname: Burnstein
authors.forename: Kathryn E
authors.initials: KE
authors.lastname: Carlson
authors.forename: John A
authors.initials: JA
authors.lastname: Katzenellenbogen
authors.forename: Miguel
authors.initials: M
authors.lastname: Vizoso
authors.forename: Manel
authors.initials: M
authors.lastname: Esteller
authors.forename: Alberto
authors.initials: A
authors.lastname: Villanueva
authors.forename: Ana B
authors.initials: AB
authors.lastname: Rodríguez-Peña
authors.forename: Xosé R
authors.initials: XR
authors.lastname: Bustelo
authors.forename: Yusuke
authors.initials: Y
authors.lastname: Nakamura
authors.forename: Hitoshi
authors.initials: H
authors.lastname: Zembutsu
authors.forename: Olle
authors.initials: O
authors.lastname: Stål
authors.forename: Roderick L
authors.initials: RL
authors.lastname: Beijersbergen
authors.forename: Miguel Angel
authors.initials: MA
authors.lastname: Pujana
mesh_terms: D000730:Androstadienes / Q000627:therapeutic use; D018931:Antineoplastic Agents, Hormonal / Q000494:pharmacology; D047072:Aromatase Inhibitors / Q000627:therapeutic use; D014408:Biomarkers, Tumor / Q000235:genetics; D001940:Breast / Q000473:pathology; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000235:genetics / Q000473:pathology; D045744:Cell Line, Tumor; D049109:Cell Proliferation / Q000187:drug effects; D002470:Cell Survival / Q000187:drug effects; D019008:Drug Resistance, Neoplasm / Q000235:genetics*; D020536:Enzyme Activators / Q000494:pharmacology; D066246:ErbB Receptors / Q000037:antagonists & inhibitors; D000069347:Erlotinib Hydrochloride; D047628:Estrogen Receptor alpha / Q000037:antagonists & inhibitors / Q000235:genetics / Q000378:metabolism*; D005260:Female; D015972:Gene Expression Regulation, Neoplastic; D056726:Genetic Association Studies; D014644:Genetic Variation; D006801:Humans; D007191:Indazoles / Q000494:pharmacology*; D000077289:Letrozole; D061986:MCF-7 Cells; D009570:Nitriles / Q000627:therapeutic use; D047428:Protein Kinase Inhibitors / Q000494:pharmacology; D051567:Proto-Oncogene Proteins c-vav / Q000235:genetics*; D011799:Quinazolines / Q000494:pharmacology; D034622:RNA Interference; D034741:RNA, Small Interfering; D013629:Tamoxifen / Q000494:pharmacology / Q000627:therapeutic use; D017312:Toremifene / Q000494:pharmacology / Q000627:therapeutic use; D014230:Triazoles / Q000627:therapeutic use
chemical_list: D000730:Androstadienes; D018931:Antineoplastic Agents, Hormonal; D047072:Aromatase Inhibitors; D014408:Biomarkers, Tumor; C506487:ESR1 protein, human; D020536:Enzyme Activators; D047628:Estrogen Receptor alpha; D007191:Indazoles; D009570:Nitriles; D047428:Protein Kinase Inhibitors; D051567:Proto-Oncogene Proteins c-vav; D011799:Quinazolines; D034741:RNA, Small Interfering; D014230:Triazoles; C496621:VAV3 protein, human; D013629:Tamoxifen; C090937:3-(5'-hydroxymethyl-2'-furyl)-1-benzylindazole; D000077289:Letrozole; D017312:Toremifene; D000069347:Erlotinib Hydrochloride; D066246:ErbB Receptors; C056516:exemestane